Colorectal cancer patients with different C reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics

Show full item record



Permalink

http://hdl.handle.net/10138/235215

Citation

Holm , M , Saraswat , M , Joenväärä , S , Ristimäki , A , Haglund , C & Renkonen , R 2018 , ' Colorectal cancer patients with different C reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics ' , PLoS One , vol. 13 , no. 4 , 0195354 . https://doi.org/10.1371/journal.pone.0195354

Title: Colorectal cancer patients with different C reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics
Author: Holm, Matilda; Saraswat, Mayank; Joenväärä, Sakari; Ristimäki, Ari; Haglund, Caj; Renkonen, Risto
Contributor organization: Doctoral Programme in Biomedicine
HUSLAB
Transplantation Laboratory
Department of Pathology
University Management
Gastrointestinal tumorigenesis
HUS Abdominal Center
Doctoral Programme in Oral Sciences
Doctoral Programme in Clinical Research
Department of Surgery
II kirurgian klinikka
Department of Bacteriology and Immunology
Infection Biology Research Program
Risto Renkonen / Principal Investigator
Date: 2018-04-09
Language: eng
Number of pages: 18
Belongs to series: PLoS One
ISSN: 1932-6203
DOI: https://doi.org/10.1371/journal.pone.0195354
URI: http://hdl.handle.net/10138/235215
Abstract: Over 1.4 million people are diagnosed with colorectal cancer (CRC) each year, making it the third most common cancer in the world. Increased screening and therapeutic modalities including improved combination treatments have reduced CRC mortality, although incidence and mortality rates are still increasing in some areas. Serum-based biomarkers are mainly used for follow-up of cancer, and are ideal due to the ease and minimally invasive nature of sample collection. Unfortunately, CEA and other serum markers have too low sensitivity for screening and preoperative diagnostic purposes. Increasing interest is focused on the possible use of biomarkers for predicting treatment response and prognosis in cancer. In this study, we have performed mass spectrometry analysis (UPLC-UDMSE) of serum samples from 19 CRC patients. Increased levels of C-reactive protein (CRP), which occur during local inflammation and the presence of a systemic inflammatory response, have been linked to poor prognosis in CRC patients. We chose to analyze samples according to CRP values by dividing them into the categories CRP 30, and, separately, according to short and long 5-year survival. The aim was to discover differentially expressed proteins associated with poor prognosis and shorter survival. We quantified 256 proteins and performed detailed statistical analyses and pathway analysis. We discovered multiple proteins that are up- or downregulated in patients with CRP >30 as compared to CRP
Subject: BINDING PROTEIN-2
COLON-CANCER
AMYLOID-A
PANCREATIC-CANCER
POOR-PROGNOSIS
BIOMARKER
INSULIN
ANTIGEN
IDENTIFICATION
CHOLESTEROL
3126 Surgery, anesthesiology, intensive care, radiology
3122 Cancers
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
file.pdf 6.545Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record